论文部分内容阅读
【目的】研究GPR30在卵巢癌中的亚细胞定位及临床意义。【方法】应用免疫组化技术检测我院2000-2010年的110例卵巢癌组织中GPR30的表达,分析GPR30与卵巢癌的临床病理特点的关系。同时应用流式分选技术和免疫荧光技术检测GPR30在卵巢癌的亚细胞定位。【结果】GPR30在62.7%的卵巢癌组织中表达,其中包括51例浆液性腺癌和4例黏液性腺癌中(P=0.102)。肿瘤残余组(R1,33/45)中GPR30表达率高于无残留组(R0,34/65),具有统计学差异(P=0.030)。在卵巢癌复发组中,73.7%的卵巢癌组织(42/57)可检测到GPR30表达阳性,而GPR30在50.9%的非复发组卵巢癌组织(27/53)中表达阳性(P=0.018)。进展型卵巢癌及低分化卵巢癌中GPR30表达率较早期卵巢癌和高分化卵巢癌中GPR30表达率高,但无统计学差异。5年随访发现,存活的患者中有33例的卵巢癌组织表达GPR30,而GPR30表达于66.7%的死亡病例中,二者无统计学差异。流式分选及免疫荧光技术卵巢癌细胞系SKOV-3细胞内GPR30表达,其中细胞核上GPR30表达明显高于细胞质上GPR30。【结论】GPR30表达阳性的卵巢癌肿瘤残留率、术后复发率增加,不同病理类型、临床病理分期及组织分级的卵巢癌中GPR30表达无明显差异。卵巢癌细胞中GPR30具有核聚集表达现象,从而诱导卵巢癌发生发展的新机制。
【Objective】 To investigate the subcellular localization of GPR30 in ovarian cancer and its clinical significance. 【Methods】 The expression of GPR30 in 110 cases of ovarian cancer from 2000 to 2010 in our hospital was detected by immunohistochemistry. The relationship between GPR30 and the clinicopathological features of ovarian cancer was analyzed. At the same time, flow cytometry and immunofluorescence were used to detect subcellular localization of GPR30 in ovarian cancer. [Results] GPR30 was expressed in 62.7% of ovarian cancer tissues, including 51 cases of serous adenocarcinoma and 4 cases of mucinous adenocarcinoma (P = 0.102). The rate of GPR30 expression in the residual tumor group (R1, 33/45) was higher than that in the non-residual group (R0, 34/65), with statistical difference (P = 0.030). In ovarian cancer recurrence group, GPR30 expression was detectable in 73.7% of ovarian cancer tissues (42/57), while GPR30 was positive in 50.9% of non-recurrent ovarian cancer tissues (27/53) (P = 0.018) . GPR30 expression rate in advanced ovarian cancer and poorly differentiated ovarian cancer is higher than that in early ovarian cancer and well-differentiated ovarian cancer, but there is no statistical difference. At 5-year follow-up, GPR30 was expressed in 33 of the surviving patients and in 66.7% of the deaths, with no significant difference between the two groups. Flow cytometry and immunofluorescence showed that the expression of GPR30 in the ovarian cancer cell line SKOV-3 was significantly higher than that in the cytoplasm GPR30. 【Conclusions】 The residual rate of GPR30-positive ovarian cancer and the recurrence rate of GPR30 are increased. There is no significant difference in the expression of GPR30 in different pathological types, clinicopathological stages and histological grade of ovarian cancer. Overexpression of GPR30 in ovarian cancer cells can induce the development of ovarian cancer.